Courier service EMS
Other transport services
Air India Post International
Payment in the bank on the invoice
WestrUnion
MoneyGram
Sprycel 20mg is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukaemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrin’s and GFR. Sprycel 20mg is a prescription drug which used under the supervision of doctor.
Sprycel 20mg is indicated for the treatment for
Newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase.
Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy
Dasatinib is a group of drugs called a protein tyrosine kinase inhibitor (TKI).
Multi-kinase inhibitor which prohibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-Kit, EPHA2 and PDGFR-beta kinases; tyrosine kinase prevention of possibly stops angiogenesis and cellular proliferation
Distribution: volume of distribution 2505 L and plasma protein binding is 96%
Metabolism: Extensively metabolized in humans, mainly by the cytochrome P450 enzyme 3A4.
Elimination: Dasatinib excreted through the feces.
Half-life is 3-5 hours
Newly diagnosed
The recommended dose: starting 100 mg PO qDay (morning or evening).
May raised to 140 mg qDay if insufficient response.
Advanced CML
The recommended dose: starting 140 mg PO qDay
May increase to 180 mg qDay if insufficient reactions
The recommended dose: starting 140 mg PO qDay
May increase to 180 mg PO qDay if insufficient reactions
Sprycel 20mg will cause fetal harm while using during pregnancy. Advise a pregnant woman of the possible risk to a foetus.
Avoid breastfeeding during Sprycel treatment.
Stored at 200C – 250C
In case of missed dose, patients must consult with medical oncologist and follow the regular dosing schedule.